Riskpilot← Back to searchSign inGet full accessSulis Therapeutics ApS
APSActiveCVR 44445832Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20232 employees
Revenue 2024
DKK -167K
+8203% vs 2023
EBITDA margin
116.7%
-9586% vs 2023
Equity ratio
-8.6%
Financial strength
Net profit 2024
DKK -202K
-4356% vs 2023
| Revenue | DKK -167K | +8203% |
| EBITDA | DKK -195K | -9586% |
| Net profit | DKK -202K | -4356% |
| Total assets | DKK 533K | +172% |
| Equity | DKK -46K | -129% |
| Employees | 2 | — |
Legal name
Sulis Therapeutics ApS
CVR number
44445832
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. november 2023
Share capital
DKK 100.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem, eller af den samlede bestyrelse.
Company purpose
Selskabets formål er udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Address
Ole Maaløes Vej 3
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | -2 | -167 |
| Staff expenses | -0 | -28 |
| EBITDA | -2 | -195 |
| Depreciation & amort. | -3 | -30 |
| EBIT | -5 | -225 |
| Net financials | 0 | -11 |
| Profit before tax | -5 | -236 |
| Tax | -0 | -34 |
| Net profit | -5 | -202 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 196 | 533 |
| Equity | 156 | -46 |
| Long-term debt | 0 | 546 |
| Short-term debt | 40 | 33 |
| Total debt | 40 | 579 |
EBITDA margin
-19498200.0%
This company
15.8%
Market median
-123406429% vs market
20232024
Equity ratio
-8.6%
This company
38.2%
Market median
-123% vs market
20232024
Return on equity
-20231400.0%
This company
18.4%
Market median
-109953361% vs market
20232024
Net profit margin
-20231400.0%
This company
8.1%
Market median
-249770470% vs market
20232024
Asset turnover
-0.31×
This company
1.12×
Market median
-128% vs market
20232024
Debt / equity
12.64×
This company
0.62×
Market median
-1939% vs market
20232024
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2025 | |
| Board of Directors | 2025 | |
| Former (5) | ||
| Board of Directors | 2023 – 2024 | |
| Chairman | 2023 – 2024 | |
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2023 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2024 | |
| Individual | 25–33.32% | 25–33.32% | 2024 | |
| Company | 15–19.99% | 15–19.99% | 2024 | |
| Company | 20–24.99% | 20–24.99% | 2023 | |
| Company | 20–24.99% | 20–24.99% | 2023 | |
| Individual | 20–24.99% | 20–24.99% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MR Jakobsen Holding ApS
Sulis Therapeutics ApS Board members of Sulis Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Døssing | Board of Directors | 0 companies |
| Christian Schetter | Chairman | 0 companies |
| Natalie Rose Sacks | Board of Directors | 0 companies |
| Regina Hodits | Board of Directors | 0 companies |
| Sten Verland | Board of Directors | 0 companies |
| Claus Elsborg Olesen | Chairman | 0 companies |
| Martin Roelsgaard Jakobsen | Board of Directors | 0 companies |